ADCendo: entering tumors via MRC2

How ADCendo is targeting MRC2 for safe, effective treatment of sarcoma

ADCendo ApS is developing an antibody-drug conjugate against mannose receptor C type 2 (MRC2; UPARAP) that could treat cancers at lower doses and with less toxicity than other ADCs, due to the target’s enriched cancer expression and cellular internalization properties.

MRC2 is an endocytic receptor that internalizes the molecules it binds with high efficiency, delivers them for lysosomal

Read the full 574 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE